Supplementary Table 3 Treatment-emergent adverse events regardless of relation to study drug leading to regorafenib dose reduction

n (%)	**Regorafenib (N=100)**		
	Grade 3	Grade 4	Any grade
Any TEAE leading to dose reduction[a]	7 (7)	0	30 (30)
HFSR	1 (1)	0	8 (8)
Fatigue	1 (1)	0	7 (7)
Blood bilirubin increased	1 (1)	0	2 (2)
Hypophosphatemia	0	0	2 (2)
Lipase increased	0	0	2 (2)
Maculopapular rash	1 (1)	0	2 (2)

Events and grades by CTCAE v4.0.
[a]Individual events listed are those occurring in ≥2% of patients.
CTCAE=Common Terminology Criteria for Adverse Events; HFSR=hand–foot skin reaction; TEAE=treatment-emergent adverse event.